Nascent Pharma Holdings (NASC) Stock Overview
Engages in the protection and commercialization of cannabis patents. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NASC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Nascent Pharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.01 |
| 52 Week High | US$0.036 |
| 52 Week Low | US$0.006 |
| Beta | 0 |
| 1 Month Change | 23.81% |
| 3 Month Change | -20.66% |
| 1 Year Change | -58.40% |
| 3 Year Change | -87.76% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| NASC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 6.1% | 1.9% | -0.2% |
| 1Y | -58.4% | 47.6% | 12.1% |
Return vs Industry: NASC underperformed the US Pharmaceuticals industry which returned 47.6% over the past year.
Return vs Market: NASC underperformed the US Market which returned 12.1% over the past year.
Price Volatility
| NASC volatility | |
|---|---|
| NASC Average Weekly Movement | 41.1% |
| Pharmaceuticals Industry Average Movement | 8.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NASC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NASC's weekly volatility has increased from 32% to 41% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Marco Alfonsi | nascentpharmaholdings.com |
Nascent Pharma Holdings, Inc. engages in the protection and commercialization of cannabis patents. It produces superfood drink mix products under the Longevity brand name. The company was formerly known as Can B Corp. and changed its name to Nascent Pharma Holdings, Inc. in September 2025.
Nascent Pharma Holdings, Inc. Fundamentals Summary
| NASC fundamental statistics | |
|---|---|
| Market cap | US$1.51m |
| Earnings (TTM) | -US$13.26m |
| Revenue (TTM) | US$1.03m |
Is NASC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NASC income statement (TTM) | |
|---|---|
| Revenue | US$1.03m |
| Cost of Revenue | US$1.38m |
| Gross Profit | -US$343.30k |
| Other Expenses | US$12.92m |
| Earnings | -US$13.26m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NASC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/20 18:31 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nascent Pharma Holdings, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Gregozeski | Greenridge Global LLC |